secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001867096-25-000085
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Q1 revenue up 48% to $60.1M; Recorlev surges 141%; tightens FY guidance to $260-275M
--------------------------------------------------------------------------------

- Total revenue $60.1M (+48% YoY); net loss $9.2M ($0.06 loss per share) vs prior year loss.
- Recorlev revenue $25.5M (+141%); Gvoke $20.8M (+26%); Keveyis $11.4M (-13%).
- Adjusted EBITDA positive $4.4M, an improvement of $8.4M vs Q1 2024.
- FY 2025 total revenue guidance tightened to $260M-$275M from $255M-$275M.
- Announces Analyst & Investor Day on June 3, 2025 in NYC to discuss Recorlev and XP-8121.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000085/0001867096-25-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000085/xers-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer